A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

• Status: Terminated
• Trial end date: 2014-08-05
• Target enrollment: 0
• Participant gender: All

Summary

This prospective, observational, multicentre, post marketing surveillance study will collect safety and efficacy information on patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN) treated with Cetuximab and Radiotherapy (RT) based on the locally approved label.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck KGaA; Merck KGaA, Darmstadt, Germany
• Collaborator: Merck Ltd., India
• Treatments: Cetuximab

Criteria

Inclusion Criteria:

• Inclusion criteria as per the product label for LA SCCHN approved by India Health Authority

• Unresectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck

• Patient willing and able to give written Informed Consent

• Patient capable of complying with study data collection procedures

Exclusion Criteria:

• Exclusion criteria as per the product label for LA SCCHN approved by India Health Authority